ProfileGDS5678 / 1416395_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 87% 84% 85% 87% 86% 86% 84% 85% 85% 85% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5771887
GSM967853U87-EV human glioblastoma xenograft - Control 26.5413986
GSM967854U87-EV human glioblastoma xenograft - Control 36.6390787
GSM967855U87-EV human glioblastoma xenograft - Control 46.4205984
GSM967856U87-EV human glioblastoma xenograft - Control 56.4379285
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4668887
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4139186
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4499386
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2324884
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4602485
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3979485
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4322385
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4660386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5667886